Omnicell (NASDAQ:OMCL) Raised to Strong-Buy at Zacks Research

Omnicell (NASDAQ:OMCL) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Wednesday, Zacks reports.

Several other research firms also recently weighed in on OMCL. Weiss Ratings raised shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Finally, Wells Fargo & Company decreased their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Omnicell currently has a consensus rating of “Buy” and a consensus price target of $57.86.

Omnicell Trading Down 3.5%

Shares of OMCL opened at $38.03 on Wednesday. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of 39.61, a PEG ratio of 0.98 and a beta of 0.88. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.45 and a current ratio of 1.65. Omnicell has a fifty-two week low of $31.75 and a fifty-two week high of $55.00. The firm has a 50 day moving average price of $34.85 and a 200-day moving average price of $38.84.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The company had revenue of $307.85 million during the quarter, compared to analysts’ expectations of $304.44 million. During the same quarter in the prior year, the company earned $0.51 EPS. The firm’s revenue was down .9% on a year-over-year basis. As a group, equities research analysts forecast that Omnicell will post 1.64 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OMCL. BlackRock Inc. bought a new position in shares of Omnicell during the second quarter valued at $313,044,000. Dimensional Fund Advisors LP boosted its stake in Omnicell by 6.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company’s stock worth $81,791,000 after purchasing an additional 137,834 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its stake in Omnicell by 2.0% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,410,865 shares of the company’s stock worth $47,095,000 after purchasing an additional 27,497 shares in the last quarter. Bank of America Corp DE grew its position in Omnicell by 31.3% during the 1st quarter. Bank of America Corp DE now owns 580,875 shares of the company’s stock valued at $19,390,000 after purchasing an additional 138,537 shares during the last quarter. Finally, First Light Asset Management LLC purchased a new stake in Omnicell during the 1st quarter valued at about $16,351,000. Institutional investors own 97.70% of the company’s stock.

Trending Headlines about Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks Research upgraded Omnicell from “Hold” to “Strong Buy,” reinforcing the positive outlook. Zacks Research ratings
• Positive Sentiment: Zacks cited solid upward earnings-estimate revisions and added OMCL to its Strong Buy and momentum lists—signals that may indicate improving near-term sentiment. Zacks earnings revisions article
• Neutral Sentiment: A Zacks article noted that analyst price targets imply about 40.8% upside, but cautioned that consensus targets alone have limited predictive value; it also pointed to the favorable estimate-revision trend. Zacks price target analysis

Omnicell Company Profile

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.